Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

Company

Corify Care SL

Corify Care SL_logo
15
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

CORIFY Care SL is a medical start-up focused on cardiac arrhythmias. We are developing a novel technology to improve the treatment of atrial fibrillation.

Madrid, Madrid, Spain

Send a message

  • 6

    employees

Anglais

Corify Care SL

Anglais

CORIFY Care SL (Corify) is a medical start-up focused on cardiac arrhythmias. We are developing a novel technology to improve the treatment of atrial fibrillation, which affects more than 30M patients worldwide. Corify vision is to become the world reference company in the prognosis and treatments of patients with cardiac arrhythmias.

Corify was founded by Andreu Climent and María Guillem, biomedical engineers, together with Felipe Atienza and Francisco Fernández-Avilés,...

See more

CORIFY Care SL (Corify) is a medical start-up focused on cardiac arrhythmias. We are developing a novel technology to improve the treatment of atrial fibrillation, which affects more than 30M patients worldwide. Corify vision is to become the world reference company in the prognosis and treatments of patients with cardiac arrhythmias.

Corify was founded by Andreu Climent and María Guillem, biomedical engineers, together with Felipe Atienza and Francisco Fernández-Avilés, world-renowned physiologists on cardiac arrhythmias. The technology originated at Hospital Universitario Gregorio Marañón (Madrid) and Universitat Politècnica de València.

The Strategic Research Agenda for cardiovascular disease (SRA-CVD) considers the improvement of the Atrial Fibrillation (AF) treatment a priority area. There are 10,7 million AF patients across Europe. By 2050, 2% of the population will be affected by AF. The effective treatment is ablation. However, more than 60% of persistent AF require several procedures, amounting to €13,5 billion in wasted healthcare costs.

Corify has developed ACORYS, a medical device, combining high-density electrodes, innovative image and biosignals processing technology and artificial intelligence. First, it helps with the diagnosis; Second, it guides surgeons during the ablation procedure.The advantage is double: a more precise diagnosis and more efficient surgery. ACORYS has been preliminarily validated with more than 150 patients in Spain and US.

Our latest news

Communities

Access2EIC – Seal of Excellence
The Access2EIC -Seal of Excellence community aims at gathering high potential European companies that received from the European Commission a “Seal of Excellence” certificate and European equity investors. https://access2eic.eu/
1931 Members